The Cancer/Oncology Drugs Market represents one of the most dynamic and innovation-driven sectors within the global ...

From antibiotic resistance to emerging viral threats, the global demand for new medicines is intensifying, yet traditional drug discovery pipelines remain slow and expensive. A new scientific review ...

Explore the OC-PAM AI tool that revolutionizes cancer research with non-invasive imaging of organoids and spheroids.

A consortium including experts from DCU and UL have developed a new strategy to design compounds capable of damaging cancer cell DNA.

Researchers studying cat cancer discovered links with human cancer that could lead to the development of a cure for both ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Explore the role of MDM2 in breast cancer and its implications for developing new treatments for triple-negative breast cancer.

A new UCLA investigator-initiated study has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic ...

ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early ...

HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, has received orphan drug designation (ODD) from the FDA for the ...

The first study of multiple cancer types in cats has identified genetic changes that could help treat the condition in humans ...

VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...